Hydrophobicity of antifungal ß-peptides is associated with their cytotoxic effect on in vitro human colon Caco-2 and liver HepG2 cells

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Mora Navarro, Camilo ^a   Méndez Vega, Janet ^a   Caraballo León, Jean ^a   Lee, Myung Ryul ^b   Palecek, Sean ^b   Torres Lugo, Madeline ^a   Ortiz Bermúdez, Patricia ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b University of Wisconsin Madison   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL BETA PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT;

ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG TRANSPORT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; IN VITRO STUDY; INTRACELLULAR TRANSPORT; STRUCTURE ACTIVITY RELATION; CACO-2 CELL LINE; CHEMICAL PHENOMENA; COLON; DRUG EFFECTS; HEP-G2 CELL LINE; LIVER;

ANTIFUNGAL AGENTS; CACO-2 CELLS; COLON; HEP G2 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIVER;

EID: 84962360737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149271     Document Type: Article

References (38)

1. World Health Organization. Antimicrobial resistance: Global report on surveillance 2014 [Internet]. Vasa. 2014. Available: Http: //medcontent.metapress.com/index/A65RM03P4874243N.pdf
2. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: Human fungal infections. Sci Transl Med. 2012; 4: 165rv13. doi: 10.1126/scitranslmed.3004404 PMID: 23253612
3. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50: 1091-100. doi: 10.1086/651263 PMID: 20218877
4. Lakshminarayanan R, Liu S, Li J, Nandhakumar M, Aung TT, Goh E, et al. Synthetic multivalent antifungal peptides effective against fungi. PLoS One. 2014; 9: E87730. doi: 10.1371/journal.pone.0087730 PMID: 24498363
5. Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, et al. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2010; 54: 3432-41. doi: 10.1128/AAC.01586-09 PMID: 20439615
6. Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009; 48: 1441-58. doi: 10.1086/598327 PMID: 19361301
7. van der Weerden NL, Bleackley MR, Anderson MA. Properties and mechanisms of action of naturally occurring antifungal peptides. Cell Mol Life Sci. 2013; 70: 3545-70. doi: 10.1007/s00018-013-1260-1 PMID: 23381653
8. Giuliani A, Pirri G, Nicoletto SF. Antimicrobial peptides: An overview of a promising class of therapeutics. Cent Eur J Biol. 2007; 2: 1-33. doi: 10.2478/s11535-007-0010-5
9. Murray JK, Gellman SH. Microwave-assisted parallel synthesis of a 14-helical beta-peptide library. J Comb Chem. 2006; 8: 58-65. doi: 10.1021/cc0501099 PMID: 16398554
10. Cabrele C, Martinek TA, Reiser O, Berlicki L. Peptides containing ß-amino acid patterns: Challenges and successes in medicinal chemistry. J Med Chem. 2014; 57: 9718-39. doi: 10.1021/jm5010896 PMID: 25207470
11. Lee M-R, Raman N, Gellman SH, Lynn DM, Palecek SP. Hydrophobicity and helicity regulate the antifungal activity of 14-helical ß-peptides. ACS Chem Biol. 2014; 9: 1613-21. doi: 10.1021/cb500203e PMID: 24837702
12. Raman N, Lee M-R, Palecek SP, Lynn DM. Polymer multilayers loaded with antifungal ß-peptides kill planktonic Candida albicans and reduce formation of fungal biofilms on the surfaces of flexible catheter tubes. J Control Release. Elsevier B.V.; 2014; 191: 54-62. doi: 10.1016/j.jconrel.2014.05.026
13. Mora-Navarro C, Caraballo-Lesn J, Torres-Lugo M, Ortiz-Berm?dez P. Synthetic antimicrobial ß -peptide in dual-treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm Candida albicans. J Pept Sci. 2015; 21: 853-861. doi: 10.1002/psc.2827 PMID: 26470850
14. Karlsson AJ, Pomerantz WC, Neilsen KJ, Gellman SH, Palecek SP. Effect of Sequence and Structural Properties on 14-Helical ß-Peptide Activity against Candida albicans Planktonic Cells and Biofilms. ACS Chem Biol. 2009; 4: 567-579.
15. Karlsson AJ, Pomerantz WC, Weisblum B, Gellman SH, Palecek SP. Antifungal activity from 14-helical beta-peptides. J Am Chem Soc. 2006; 128: 12630-1. doi: 10.1021/ja064630y PMID: 17002340
16. Björklund E, Larsson TNL, Jacobsson SOP, Fowler CJ. Ketoconazole Inhibits the Cellular Uptake of Anandamide via Inhibition of FAAH at Pharmacologically Relevant Concentrations. PLoS One. 2014; 9: E87542. doi: 10.1371/journal.pone.0087542 PMID: 24466356
17. McKim JM. Building a tiered approach to in vitro predictive toxicity screening: A focus on assays with in vivo relevance. Comb Chem High Throughput Screen. 2010; 13: 188-206. Available: Http: //www. pubmedcentral.nih.gov/articlerender.fcgi?artid=2908937& tool=pmcentrez& rendertype=abstract PMID: 20053163
18. Sahu SC, Njoroge J, Bryce SM, Yourick JJ, Sprando RL. Comparative genotoxicity of nanosilver in human liver HepG2 and colon Caco2 cells evaluated by a flow cytometric in vitro micronucleus assay. J Appl Toxicol. 2014; 34: 1226-34. doi: 10.1002/jat.3065 PMID: 25224830
19. Zhou J, Qi Y, Diao Q, Wu L, Du X, Li Y, et al. Cytotoxicity of melittin and apamin in human hepatic L02 and HepG2 cells in vitro. Toxin Rev. 2013; 32: 60-67. doi: 10.3109/15569543.2013.852108
20. Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012; 28: 69-87. doi: 10.1007/s10565-011-9208-4 PMID: 22258563
21. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol. 1997; 51: 741-54. Available: Http: //www. ncbi.nlm.nih.gov/pubmed/9145912 PMID: 9145912
22. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol. 2005; 21: 1-26. doi: 10.1007/s10565-005-0085-6 PMID: 15868485
23. Raguse TL, Porter EA, Weisblum B, Gellman SH. Structure-activity studies of 14-helical antimicrobial beta-peptides: Probing the relationship between conformational stability and antimicrobial potency. J Am Chem Soc. 2002; 124: 12774-85. Available: Http: //www.ncbi.nlm.nih.gov/pubmed/12392424 PMID: 12392424
24. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother. 2005; 56: 968-74. doi: 10.1093/jac/dki319 PMID: 16172107
25. Alvarez-Berríos MP, Castillo A, Mendéz J, Soto O, Rinaldi C, Torres-Lugo M. Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int J Nanomedicine. 2013; 8: 1003-13. doi: 10.2147/IJN.S38842 PMID: 23493492
26. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006; 1: 2315-9. doi: 10.1038/nprot.2006.339 PMID: 17406473
27. Bhat UG, Pandit B, Gartel AL. ARC synergizes with ABT-737 to induce apoptosis in human cancer cells. Mol Cancer Ther. 2010; 9: 1688-96. doi: 10.1158/1535-7163.MCT-09-0919 PMID: 20515947
28. Meek JL. Prediction of peptide retention times in high-pressure liquid chromatography on the basis of amino acid composition. Proc Natl Acad Sci. 1980; 77: 1632-1636. doi: 10.1073/pnas.77.3.1632 PMID: 6929513
29. Parker JM, Guo D, Hodges RS. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: Correlation of predicted surface residues with antigenicity and X-rayderived accessible sites. Biochemistry. 1986; 25: 5425-5432. http: //dx.doi.org/10.1021/bi00367a013 PMID: 2430611
30. Inselmann G, Inselmann U, Heidemann H. Amphotericin B and liver function. Eur J Intern Med. 2002; 13: 288-292. doi: 10.1016/S0953-6205(02)00065-1 PMID: 12144907
31. Ménez C, Buyse M, Besnard M, Farinotti R, Loiseau PM, Barratt G. Interaction between miltefosine and amphotericin B: Consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob Agents Chemother. 2006; 50: 3793-800. doi: 10.1128/AAC.00837-06 PMID: 16966395
32. Conradi R, Hilgers A, Ho NH, Burton P. The Influence of Peptide Structure on Transport Across Caco-2 Cells. Pharm Res. Kluwer Academic Publishers-Plenum Publishers; 1991; 8: 1453-1460. doi: 10.1023/A: 1015825912542
33. Pauletti G, Okumu F, Borchardt R. Effect of Size and Charge on the Passive Diffusion of Peptides Across Caco-2 Cell Monolayers via the Paracellular Pathway. Pharm Res. Kluwer Academic Publishers- Plenum Publishers; 1997; 14: 164-168. doi: 10.1023/A: 1012040425146
34. Murray JK, Gellman SH. Application of microwave irradiation to the synthesis of 14-helical beta-peptides. Org Lett. 2005; 7: 1517-20. doi: 10.1021/ol0501727 PMID: 15816741
35. Gupta N, Lamborn K, Deen DF. COMMUNICATION A Statistical Approach for Analyzing Clonogenic Survival Data. Radiat Reserch Soc. 1996; 145: 636-640.
36. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003; 22: 7414-30. doi: 10.1038/sj.onc.1206945 PMID: 14576849
37. Domenech M, Marrero-Berrios I, Torres-Lugo M, Rinaldi C. Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano. 2013; 7: 5091-101. doi: 10. 1021/nn4007048 PMID: 23705969
38. Zhao M, Eaton JW, Brunk UT. Protection against oxidant-mediated lysosomal rupture: A new anti-apoptotic activity of Bcl-2? FEBS Lett. 2000; 485: 104-8. Available: Http: //www.ncbi.nlm.nih.gov/pubmed/11094149 PMID: 11094149